Trial Profile
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 9DX
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 20 Jan 2023 Planned primary completion date changed from 16 Dec 2024 to 28 Apr 2025.
- 31 Aug 2022 Planned primary completion date changed from 15 Dec 2023 to 16 Dec 2024.
- 29 Apr 2022 Planned primary completion date changed from 14 Dec 2023 to 15 Dec 2023.